Farzad Nasri
Impact in
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- Signaling Pathways in Disease 1
-
- Galectins and Cancer Biology 2
- Immunotherapy and Immune Responses 2
- Co-authors
- Pouria Khani (6 shared papers)Reza Falak (4 shared papers)Reza Zolfaghari Emameh (1 shared paper)Asieh Hosseini (1 shared paper)Johan Garssen (1 shared paper)Hamed Mirzaei (2 shared papers)Javid Sadri Nahand (1 shared paper)Mohammad Reza Bolouri (3 shared papers)
- Journals
- Biomarker Research (1 paper)Journal of Sustainable Finance & Investment (1 paper)Research in Pharmaceutical Sciences (1 paper)Cancer Cell International (1 paper)Frontiers in Genetics (1 paper)
- Partner nations
- IranNetherlandsTunisia
In The Last Decade
Farzad Nasri
11 papers receiving 383 citations
Farzad Nasri's Hit Papers
Peers
Comparison fields: 5 of 86
- Cancer Research 93
- Drug Discovery 1
- Biomaterials 64
- Molecular Medicine 14
- Oncology 72
Countries citing papers authored by Farzad Nasri
This map shows the geographic impact of Farzad Nasri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farzad Nasri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farzad Nasri more than expected).
Fields of papers citing papers by Farzad Nasri
This network shows the impact of papers produced by Farzad Nasri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farzad Nasri. The network helps show where Farzad Nasri may publish in the future.
Co-authors
The 25 scholars most cited alongside Farzad Nasri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Chemotherapy: a double-edged sword in cancer treatment Hit paper breakdown → | 2021 | 235 |
| 2 | 2018 | 84 | |
| 3 | 2018 | 20 | |
| 4 | 2024 | 11 | |
| 5 | 2020 | 11 | |
| 6 | 2020 | 9 | |
| 7 | 2020 | 5 | |
| 8 | [Effect of carboplatin on the pharmacokinetics of melphalan administered intravenously]. | 1994 | 5 |
| 9 | 2025 | 4 | |
| 10 | 2012 | 3 | |
| 11 | 2025 | 1 | |
| 12 | 2023 | 0 | |
| 13 | 2024 | 0 |
About Farzad Nasri
Farzad Nasri is a scholar working on Molecular Biology, Immunology, Pathology and Forensic Medicine, Oncology and Cancer Research, having authored 13 papers that have together received 388 indexed citations. Recurring topics across this work include Galectins and Cancer Biology (2 papers), Immunotherapy and Immune Responses (2 papers), Autoimmune Bullous Skin Diseases (1 paper), Signaling Pathways in Disease (1 paper), MicroRNA in disease regulation (1 paper), Allergic Rhinitis and Sensitization (1 paper), Computational Drug Discovery Methods (1 paper) and Dermatology and Skin Diseases (1 paper). The work is most often cited by research in Cancer Research (93 citations), Drug Discovery (1 citation), Biomaterials (64 citations), Molecular Medicine (14 citations) and Oncology (72 citations). Farzad Nasri has collaborated with scholars based in Iran, Netherlands and Tunisia. Frequent co-authors include Pouria Khani, Reza Falak, Reza Zolfaghari Emameh, Asieh Hosseini, Johan Garssen, Hamed Mirzaei, Javid Sadri Nahand, Mohammad Reza Bolouri, Ali Zekri and Elham Behrangi. Their work appears in journals such as Biomarker Research, Journal of Sustainable Finance & Investment, Research in Pharmaceutical Sciences, Cancer Cell International and Frontiers in Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.